Table III.

Number of patients with the four polymorphisms and their association with prediabetes and type 2 diabetes in the whole sample set, based on three genetic models.

						Additive model		Dominant model		Recessive model
Variable	Wild-type homozygote	Heterozygote	Variant homozygote	Major allele	Minor allele	OR (95%CI)b	P	OR (95% CI)b	P	OR (95% CI)b	P	HWE
IGF2BP2 rs11705701												0.17
Controls	360	190	17	910	224	Reference		Reference		Reference
Prediabetes	268	162	31	698	224	0.79 (0.63–0.98)	0.03a	0.44 (0.23–0.83)	0.01a	0.83 (0.63–1.08)	0.17
Type 2 diabetes	280	162	19	722	200	0.70 (0.35–1.42)	0.32	0.70 (0.35–1.42)	0.32	0.94 (0.72–1.23)	0.67
IRS1 rs7578326
Controls	401	134	15	936	164	Reference		Reference		Reference		0.35
Prediabetes	349	111	8	809	127	0.90 (0.69–1.17)	0.44	0.91 (0.68–1.22)	0.55	0.67 (0.27–1.70)	0.41
Type 2 diabetes	363	118	6	844	130	0.89 (0.69–1.16)	0.41	0.93 (0.69–1.24)	0.62	0.51 (0.19–1.39)	0.19
GIPR rs10423928
Controls	362	171	20	895	211	Reference		Reference		Reference		0.97
Prediabetes	309	146	14	764	174	0.98 (0.77–1.24)	0.86	0.99 (0.76–1.31)	0.99	0.83 (0.40–1.72)	0.63
Type 2 diabetes	318	151	18	787	187	1.03 (0.81–1.30)	0.79	1.03 (0.78–1.35)	0.82	1.08 (0.54–2.15)	0.82
TCF7L2 rs12255372
Controls	208	283	72	699	427	Reference		Reference		Reference		0.10
Prediabetes	194	203	64	591	331	0.88 (0.73–1.07)	0.22	0.80 (0.61–1.04)	0.10	0.98 (0.67–1.44)	0.93
Type 2 diabetes	195	194	71	584	336	0.90 (0.74–1.09)	0.30	0.78 (0.60–1.01)	0.06	1.10 (0.76–1.60)	0.59

^aStatistically significant difference.

^bAdjusted for age and body mass index. OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium; IGF2BP2, insulin-like growth factor 2 mRNA-binding protein 2; IRS1, insulin receptor substrate 1; GIPR, gastric inhibitory polypeptide receptor; TCF7L2, transcription factor 7-like 2.